Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income: 2019-2024

Historic Net Income for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$235.8 million.

  • Centessa Pharmaceuticals' Net Income fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • According to the latest figures from FY2024, Centessa Pharmaceuticals' Net Income is -$235.8 million, which was down 56.04% from -$151.1 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Net Income peaked at -$10.7 million during FY2020, and registered a low of -$381.1 million during FY2021.
  • Moreover, its 3-year median value for Net Income was -$216.2 million (2022), whereas its average is -$201.0 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 3,473.77% in 2021, then skyrocketed by 43.26% in 2022.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' Net Income stood at -$10.7 million in 2020, then tumbled by 3,473.77% to -$381.1 million in 2021, then surged by 43.26% to -$216.2 million in 2022, then soared by 30.12% to -$151.1 million in 2023, then plummeted by 56.04% to -$235.8 million in 2024.